pSivida Corp. (PSDV) announced positive safety data from its ongoing assessment of masked safety data from its first Phase III clinical trial of Medidur for posterior uveitis, a blinding eye disease. At three months, only 4% more study eyes (2/3 of which received Medidur) experienced elevated intraocular pressure than the fellow non-study eyes.
Medidur is an injectable micro-insert designed to treat posterior uveitis that provides sustained release of flucinolone acetonide (a corticosteroid) for three years.
Paul Ashton, CEO of pSivida, said: "A significant treatment challenge with posterior uveitis patients is managing the serious side effects of prolonged steroid use, the current first-line treatment. A therapy that can provide the benefits of steroids on a sustained basis for three years with a single injection with a lower incidence of side effects would be a very significant advance in treatment of this disease."
The company expects top line results from the first Phase III trial of Medidur to be available in the second quarter of 2016.
For comments and feedback contact: editorial@rttnews.com
Business News